Price$0.28-0.01 (-2.07%)
01:45 PM07:45 PM
News · 26 weeks36+57%
2025-10-262026-04-19
Mix2290d
- SEC Filings16(73%)
- Other2(9%)
- Insider2(9%)
- M&A1(5%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 424B3 filed by Aditxt Inc.424B3 - Aditxt, Inc. (0001726711) (Filer)
- INSIDERLarge owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERNew insider Hrt Financial Lp claimed ownership of 133,574 units of Class A Shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- SECSEC Form EFFECT filed by Aditxt Inc.EFFECT - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form S-3 filed by Aditxt Inc.S-3 - Aditxt, Inc. (0001726711) (Filer)
- SECAmendment: Aditxt Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form DEF 14A filed by Aditxt Inc.DEF 14A - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Other Events8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form 10-K filed by Aditxt Inc.10-K - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form 424B5 filed by Aditxt Inc.424B5 - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form PRE 14A filed by Aditxt Inc.PRE 14A - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive OfficerBusch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
- SECAditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy SelectionIgnite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt
- SECAditxt Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the reconvened special meeting held on February 13, 2026, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025877. As a r
- SECAditxt Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form SCHEDULE 13G filed by Aditxt Inc.SCHEDULE 13G - Aditxt, Inc. (0001726711) (Subject)
- SECAditxt Inc. filed SEC Form 8-K: Other Events8-K - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Other Events8-K - Aditxt, Inc. (0001726711) (Filer)
- INSIDERDirector Brady Brian Michael sold $2 worth of shares (1 units at $1.75), decreasing direct ownership by 25% to 3 units (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- SECSEC Form DEF 14A filed by Aditxt Inc.DEF 14A - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form 424B5 filed by Aditxt Inc.424B5 - Aditxt, Inc. (0001726711) (Filer)